EC
PRVL

EcoR1 Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

EcoR1 Capital’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-367,218
Closed -$5.47M – 66
2020
Q2 		$5.47M Sell
367,218
-1,881,088
-84% -$29M 0.4% 33
2020
Q1 		$27.4M Hold
2,248,306
– – 2.86% 15
2019
Q4 		$35.6M Sell
2,248,306
-144,250
-6% -$1.84M 3.21% 11
2019
Q3 		$29.4M Hold
2,392,556
– – 3.71% 11
2019
Q2 		$31.6M Buy
+2,392,556
New +$34.9M 3.19% 12

Other funds holding PRVL

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EcoR1 Capital's PRVL Position: Q3 2020 in Review

EcoR1 Capital sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q3 2020, closing a stake of 367,218 shares — an estimated $5.47M sold.

EcoR1 Capital first reported a position in PRVL in Q2 2019 and held it in 5 quarters. The position peaked at $35.6M in Q4 2019. 76 funds tracked by Wall St. Rank hold PRVL as of Q3 2020.

  • EcoR1 Capital reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • EcoR1 Capital sold 367,218 Prevail Therapeutics Inc. Common Stock shares in Q3 2020, an estimated $5.47M.
  • EcoR1 Capital first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 5 quarters.
  • EcoR1 Capital's Prevail Therapeutics Inc. Common Stock position peaked at $35.6M in Q4 2019.
  • 76 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q3 2020.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.